Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, provides an overview of remaining challenges in managing movement disorders, including the need for enhanced neuroprotection in patients. Targeting symptoms that levodopa do not treat including psychosis, cognitive impairment, insomnia and dyskinesia are important clinical needs, as well as developing novel therapies and devices that can sustain the effect of levodopa. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.